Saturday 17 October 2026
Export VERU’s income statement to Excel — free account
Veru Inc.
VERU Healthcare Biotechnology
In the quarter to June 2026, EPS grew 40.0% and free cash flow was flat, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for three; insiders bought in the last twelve months.
2.30
0.14
−5.74%
Follow VERU
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(89.74%) | (59.96%) | (49.98%) | (62.25%) | |
| (50.36%) | (43.74%) | (36.84%) | (42.29%) | ||
ROIC |
(120,852.54%) | (720.95%) | (295.68%) | (464.03%) | |
Return on Tangible Assets |
(197.71%) | (63.68%) | (49.35%) | (63.73%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.05) | (1.22) | (1.13) | (1.13) | |
Free Cash Flow |
(30.04) | (24.88) | (26.06) | (26.04) | |
Capital Expenditures |
0.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(81.97%) | (34.31%) | (39.75%) | (48.08%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.32 | 1.30 | 1.87 | 1.91 | |
Depreciation/Fixed assets |
0.42 | 0.34 | 0.37 | 0.40 | |
Capex/Depreciation |
(0.01) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.05) | (1.22) | (1.13) | (1.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates